vTv Therapeutics to Participate in the 38th Annual ROTH Conference

vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company based in High Point, North Carolina, is set to participate in the 38th Annual ROTH Conference, taking place from March 22-24, 2026, in Dana Point, California. The company will engage in a fireside chat, along with conducting one-on-one investor meetings. The fireside chat is scheduled for March 23, 2026, at 10:00 AM PDT, and interested parties can access a live webcast through the company's website, with a replay available afterward.

vTv Therapeutics is primarily focused on developing innovative oral therapies for the treatment of diabetes and other chronic ailments. Their leading candidate, cadisegliatin (TTP399), is currently in a Phase 3 clinical trial in the United States. This potential first-in-class oral glucokinase activator aims to serve as an adjunctive therapy to insulin for individuals with type 1 diabetes (T1D). In preclinical studies, cadisegliatin has shown promise by enhancing glucokinase activity in the liver without depending on insulin, thereby potentially improving glycemic control through increased hepatic glucose uptake and glycogen storage.

Cadisegliatin has garnered recognition, having received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA). While exciting developments are underway, vTv acknowledges that the safety and efficacy of cadisegliatin have yet to be fully established, and there is no guarantee of regulatory approval or future commercial availability.

For more information on vTv Therapeutics and its pipeline, visit vtvtherapeutics.com or connect with them on LinkedIn or X. The company is also accessible for investor inquiries through LifeSci Advisors and media-related questions via TellMed Strategies.

As vTv Therapeutics Inc. (Nasdaq: VTVT) prepares to showcase its promising candidate, cadisegliatin, at the upcoming 38th Annual ROTH Conference, this event is pivotal for investors seeking exposure to innovative biopharmaceuticals focused on diabetes treatment. vTv Therapeutics is a late-stage biopharmaceutical company that is carving a niche in the diabetes therapeutic landscape, particularly with its oral glucokinase activator, cadisegliatin. The drug, currently in a Phase 3 trial, holds the potential to be the first oral adjunctive therapy to insulin for type 1 diabetes (T1D), and it has already received Breakthrough Therapy designation from the FDA.

Investors should consider this participation at the ROTH Conference as an opportunity to gauge management's insights on the drug’s development progress and market readiness. Direct interactions through 1x1 meetings and the fireside chat can provide clarity on pivotal study results and regulatory timelines. Given the landscape of diabetes care, where innovative treatments that offer improved patient compliance and convenience are in high demand, cadisegliatin could be positioned favorably to address unmet needs in T1D management.

However, due diligence is essential. While the Breakthrough designation underscores the potential promise of cadisegliatin, investors must remember that the safety and efficacy of the drug have yet to be conclusively established. As the company advances through clinical trials, market sentiment will likely closely follow the outcomes of these studies. Consequently, prospective investors should be prepared for volatility, driven by clinical trial results and regulatory announcements.

Overall, vTv Therapeutics represents a speculative yet potentially rewarding investment opportunity in the biopharmaceutical space, particularly for those with a keen interest in diabetes therapeutics. Keeping abreast of developments from the ROTH Conference could provide valuable insights for strategic investment decisions.